---
title: "Forte Biosciences, Inc. (FBRX.US)"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/FBRX.US.md"
symbol: "FBRX.US"
name: "Forte Biosciences, Inc."
industry: "Biotechnology"
datetime: "2026-04-16T10:33:43.626Z"
locales:
  - [en](https://longbridge.com/en/quote/FBRX.US.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/FBRX.US.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/FBRX.US.md)
---

# Forte Biosciences, Inc. (FBRX.US)

## Company Overview

Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. The company’s lead product candidate is the FB-102, a proprietary anti-CD122 monoclonal antibody therapeutic candidate for various autoimmune and autoimmune-related indications, such as graft-vs-host disease, vitiligo, and alopecia areata, as well as for celiac disease and non-segmental vitiligo. Forte Biosciences, Inc.

| Item | Detail |
|------|--------|
| Industry | Biotechnology |
| Exchange | US Market |
| Website | [www.fortebiorx.com](https://www.fortebiorx.com) |

## Key Drivers
> *AI-analyzed key factors driving this stock's performance*


## Longbridge Financial Score™: 
> *Longbridge Financial Score™ — Proprietary multi-factor rating model by Longbridge*
> Updated: 1970-01-01T00:00:00.000Z

**Overall:  (0.00)**

## Valuation Analysis

| Metric | Current | Industry Ranking | High | Median | Low |
|--------|---------|-----------------|------|--------|-----|
| PE (TTM) | -8.84 | 436 | - | - | - |
| PB | 10.05 | 387 | 4.28 | 3.02 | 1.70 |
| Dividend Yield | 0.00% | - | - | - | - |

## Institutional View

### Analyst Rating Distribution

> As of 2026-04-12T04:00:00.000Z

Total Analysts: **5**

| Rating | Count | Percentage |
|--------|-------|-----------| 
| Buy | 5 | 100% |

### Target Price Forecast

| Metric | Price |
|--------|-------|
| Current Price | 31.28 |
| Highest Target | 75.00 |
| Lowest Target | 54.00 |

## References

- [Company Overview — Profile, executives, shareholders, business breakdown](https://longbridge.com/en/quote/FBRX.US/overview.md)
- [Financial Reports — Income, balance sheet, cash flow, dividends](https://longbridge.com/en/quote/FBRX.US/norm.md)
- [Related News](https://longbridge.com/en/quote/FBRX.US/news.md)
- [Filings — Company announcements and regulatory filings](https://longbridge.com/en/quote/FBRX.US/filings.md)

---

> **Disclaimer: This article is for reference only and does not constitute any investment advice.**